- Home
- MODD vs EVAX Comparison
MODD vs EVAX Comparison
Compare MODD & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MODD | EVAX |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 31.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MODD | EVAX |
|---|---|---|
| Price | $5.47 | $3.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 890.3K | 29.9K |
| Earning Date | 02-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $1.20 |
| 52 Week High | $6.16 | $12.15 |
Technical Indicators
Market Signals| Indicator | MODD | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 89.37 | 49.43 |
| Support Level | $0.45 | $2.70 |
| Resistance Level | N/A | $4.64 |
| Average True Range (ATR) | 0.35 | 0.33 |
| MACD | 0.62 | -0.01 |
| Stochastic Oscillator | 88.03 | 47.38 |
Price Performance
Historical ComparisonAbout MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.